Viewing StudyNCT03222843

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 10:18 AM
Last Modification Date: 2024-10-26 @ 12:28 PM
Study NCT ID: NCT03222843
Status: COMPLETED
Last Update Posted: 2022-08-03
First Post: 2017-07-18
Brief Title: Multicentre Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura ITP Patient
Sponsor: Jiangsu HengRui Medicine Co Ltd
Organization: Jiangsu HengRui Medicine Co Ltd
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Organization Data

Organization: Jiangsu HengRui Medicine Co Ltd
Class: INDUSTRY
Study ID: HR-TPO-III-ITP
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor: Jiangsu HengRui Medicine Co Ltd
Lead Sponsor Class: INDUSTRY
Responsible Party: None
Responsible Party Title: None
Responsible Party Type: SPONSOR
Responsible Party Affiliation: None
Old Name: None
Old Organization: None

Collaborators